Quarterly report pursuant to Section 13 or 15(d)

Related Parties

v3.23.3
Related Parties
9 Months Ended
Sep. 30, 2023
Related Parties  
Related Parties

7Related Parties

The Company uses Gendreau Consulting, LLC, a consulting firm (“Gendreau”), for drug development, clinical trial design and planning, implementation and execution of contracted activities with the clinical research organization. Gendreau’s managing member is the Company’s Chief Medical Officer (“CMO”). The Company will continue to contract the services of the CMO’s spouse through Gendreau to serve as the Company’s Medical Director and to perform certain activities in connection with the Company’s ongoing clinical development of its product candidates. During the three and nine months ended September 30, 2023 and 2022, the Company paid Gendreau $26,652 and $101,432, respectively, and $94,907 and $283,844, respectively, and had accounts payable of $2,192 and $21,000 to Gendreau as of September 30, 2023 and December 31, 2022, respectively.